ArticleBMC gastroenterology2025
Evaluating The Impact of Ring Augmentation In Sleeve Gastrectomy: A Retrospective Propensity-weighted Cohort Study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSleeve gastrectomy (SG) is the most commonly performed metabolic surgery for obesity but is associated with long-term recurrent weight gain (RWG) and recurrence of comorbidities. Ring-augmented sleeve gastrectomy (RASG) has been proposed to improve weight durability by preventing gastric dilation and loss of restriction.
methodsThis retrospective propensity-weighted cohort study compared outcomes of RASG and non-ring-augmented SG (NRASG) over two years in patients with morbid obesity. A total of 1,392 SG cases performed between 2021 and 2022 were reviewed, and after propensity score weighting, 132 RASG and 125 NRASG patients were analyzed.
resultsRASG was associated with significantly higher total and excess weight loss at two years (TWL: 47.4% vs. 38.5%; EWL: 102.8% vs. 82.0%; p < 0.001) and a complete absence of RWG, compared to a 5.6% recurrence rate in the NRASG group. Comorbidity resolution rates and nutritional deficiencies were similar across groups, while ring-related complications were rare and manageable. Endoscopic evaluation at one year showed no significant difference in GERD incidence.
conclusionThese findings suggest that RASG provides more durable weight loss without added morbidity compared to NRASG. Further prospective studies incorporating patient-reported outcomes and physiologic assessments are warranted to validate long-term benefits and safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.